NASDAQ:ALNY Alnylam Pharmaceuticals (ALNY) Stock Price, News & Analysis $227.66 +3.63 (+1.62%) Closing price 10/26/2026 04:00 PM EasternExtended Trading$229.08 +1.42 (+0.62%) As of 07:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Alnylam Pharmaceuticals Stock (NASDAQ:ALNY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ALNY alerts:Sign Up Key Stats Today's Range$224.10▼$232.4850-Day Range$219.72▼$267.4052-Week Range$197.81▼$485.36Volume1.44 million shsAverage Volume1.31 million shsMarket Capitalization$30.46 billionP/E Ratio42.32Dividend YieldN/APrice Target$364.95Consensus RatingModerate Buy Company Overview Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions. Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1. The company also maintains a pipeline of investigational RNAi medicines targeting diseases in areas such as genetic disorders, cardiometabolic conditions, and central nervous system diseases. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam serves patients internationally through its commercial operations and collaborations with other pharmaceutical companies. The company’s leadership includes President and Chief Executive Officer Yvonne Greenstreet, who has led Alnylam since 2022.AI Generated. May Contain Errors. Read More Alnylam Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks92nd Percentile Overall ScoreALNY MarketRank™: 4.58560311284 of 5 starsAlnylam Pharmaceuticals scored higher than 92% of companies evaluated by MarketBeat, and ranked 49th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingAlnylam Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 4 strong buy ratings, 16 buy ratings, 6 hold ratings, and no sell ratings.Upside PotentialAlnylam Pharmaceuticals has a consensus price target of $364.95, representing about 60.3% upside from its current price of $227.66.Amount of Analyst CoverageAlnylam Pharmaceuticals has been the subject of 21 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Alnylam Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth43.70% Earnings GrowthEarnings for Alnylam Pharmaceuticals are expected to grow by 43.70% in the coming year, from $6.43 to $9.24 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alnylam Pharmaceuticals is 42.32, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.11.Price to Earnings Ratio vs. SectorThe P/E ratio of Alnylam Pharmaceuticals is 42.32, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 35.91.Price to Book Value per Share RatioAlnylam Pharmaceuticals has a P/B Ratio of 38.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Alnylam Pharmaceuticals' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.95% of the float of Alnylam Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAlnylam Pharmaceuticals has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Alnylam Pharmaceuticals has recently decreased by 14.82%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAlnylam Pharmaceuticals does not currently pay a dividend.Dividend GrowthAlnylam Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.54 News SentimentAlnylam Pharmaceuticals has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Alnylam Pharmaceuticals this week, compared to 10 articles on an average week.Search Interest14 people have searched for ALNY on MarketBeat in the last 30 days. This is an increase of 8% compared to the previous 30 days.MarketBeat Follows7 people have added Alnylam Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Alnylam Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $398,855.00 in company stock.Percentage Held by Insiders0.86% of the stock of Alnylam Pharmaceuticals is held by insiders.Percentage Held by Institutions92.97% of the stock of Alnylam Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Alnylam Pharmaceuticals' insider trading history. Receive ALNY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALNY Stock News HeadlinesAlnylam Pharmaceuticals, Inc. (ALNY) RNAi Roundtable: Exon 1 Targeting With Brezosiran for Huntington's Disease TranscriptOctober 26 at 12:00 AM | seekingalpha.comAlnylam: Amvuttra Growth And Brezosiran Strengthen The Bull CaseOctober 26 at 10:00 AM | seekingalpha.comTwo charts tell you the future…Gold miners are posting record cash flows, outperforming every other sector, yet mining still makes up just 1% of global equities. Garrett Goggin, CFA, CMT, has spent more than 20 years studying gold cycles and mining companies. Porter Stansberry has called him the most knowledgeable gold investor in the world.October 27 at 1:00 AM | Golden Portfolio (Ad)Alnylam reports preliminary Phase Ib trial results for brezosiranOctober 26 at 8:28 AM | yahoo.comAlnylam's Brezosiran Lowers Mutant Huntingtin In Phase 1b Huntington's TrialOctober 23, 2026 | rttnews.comAlnylam Pharmaceuticals Reports 60% to 64% Huntingtin Reduction in Brezosiran TrialOctober 23, 2026 | finance.yahoo.comAlnylam Reports Positive Initial Phase 1b Results For ALN-HTT02October 23, 2026 | rttnews.comAlnylam Pharmaceuticals (NASDAQ:ALNY) EVP Bryan Supran Sells 1,758 Shares of StockOctober 7, 2026 | insidertrades.comSee More Headlines ALNY Stock Analysis - Frequently Asked Questions How have ALNY shares performed this year? Alnylam Pharmaceuticals' stock was trading at $397.65 at the beginning of 2026. Since then, ALNY shares have decreased by 42.7% and is now trading at $227.66. How were Alnylam Pharmaceuticals' earnings last quarter? Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) released its earnings results on Thursday, July, 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, beating analysts' consensus estimates of $1.63 by $0.21. The firm's revenue for the quarter was up 66.9% compared to the same quarter last year. Read the conference call transcript. Who are Alnylam Pharmaceuticals' major shareholders? Top institutional investors of Alnylam Pharmaceuticals include Assenagon Asset Management S.A. (0.13%), Slow Capital Inc. (0.01%), Robeco Institutional Asset Management B.V. (0.01%) and Maxi Investments CY Ltd (0.01%). Insiders that own company stock include Yvonne Greenstreet, Jeffrey V Poulton, Tolga Tanguler, Pushkal Garg, Kevin Joseph Fitzgerald, Michael W Bonney, Bryan Supran, Melissa Mclaughlin, Amy W Schulman, David E I Pyott, Dennis A Ausiello, Colleen F Reitan and Phillip A Sharp. View institutional ownership trends. How do I buy shares of Alnylam Pharmaceuticals? Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Alnylam Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alnylam Pharmaceuticals investors own include NVIDIA (NVDA), Tesla (TSLA), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Micron Technology (MU) and Bristol Myers Squibb (BMY). Company Calendar Last Earnings7/30/2026Today10/27/2026Next Earnings (Estimated)10/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (9m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ALNY's financial health is in the Red zone, according to TradeSmith. ALNY has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ALNY CIK1178670 Webwww.alnylam.com Phone(617) 551-8200Fax617-551-8101Employees2,770Year Founded2002Price Target and Rating Average Price Target for Alnylam Pharmaceuticals$364.95 High Price Target$489.00 Low Price Target$253.00 Potential Upside/Downside+60.3%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage26 Analysts Profitability EPS (Trailing Twelve Months)$5.38 Trailing P/E Ratio42.32 Forward P/E Ratio35.41 P/E GrowthN/ANet Income$313.75 million Net Margins15.26% Pretax Margin15.95% Return on Equity84.93% Return on Assets14.30% Debt Debt-to-Equity Ratio0.75 Current Ratio3.05 Quick Ratio2.99 Sales & Book Value Annual Sales$3.71 billion Price / Sales8.20 Cash Flow$2.84 per share Price / Cash Flow80.12 Book Value$5.97 per share Price / Book38.13Miscellaneous Outstanding Shares133,810,000Free Float132,658,000Market Cap$30.46 billion OptionableOptionable Beta0.28 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:ALNY) was last updated on 10/26/2026 by MarketBeat.com Staff. From Our Partners80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredTwo charts tell you the future…Gold miners are posting record cash flows, outperforming every other sector, yet mining still makes up just 1%...Golden Portfolio | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
